RxDoctor Payments Data

Jack Sadovnik

Optometrist · Towson, MDNPI 1619097698

Payments from drug & device makers

$1,019in general payments, 2019–2025

Across 40 payments — averaging $25.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tarsus Pharmaceuticals, Inc.$370
  • Alcon$226
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$113
  • Bausch & Lomb Americas Inc.$113
  • Johnson & Johnson Vision Care, Inc.$64
  • Sun Pharmaceutical Industries Inc.$60
  • plus $73 from 3 others

What the payments were for

  • Food & beverage$1,019100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,019 in reported general payments places this provider in the 60th percentile of 790 optometrist providers in Maryland.

See all optometrist providers in Maryland

Medicare billing

Part B allowed, 2024
$92,612
Medicare patients
539
Services billed
969

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast26$22,809
LumiganBimatoprost44$19,550
RestasisCyclosporine13$15,387
RocklatanNetarsudil Mesylat/Latanoprost25$11,901
CombiganBrimonidine Tartrate/Timolol24$6,021
Latanoprost375$3,802
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat210$3,029
Fluorometholone14$818
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol15$776
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha60$591
Brimonidine Tartrate57$535
Tobramycin-DexamethasoneTobramycin/Dexamethasone11$430
Timolol Maleate11$189

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan$22$40,95881 claims
Bausch & Lomb Americas Inc.Xiidra$113$22,80926 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 790 optometrist providers in Maryland.

Other optometrist in Towson

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →